Bayer Is Donating Its Malaria Drug That Could Help Coronavirus Patients In The U.S.
With no vaccines or treatments for COVID-19 on the market, many healthcare companies are evaluating existing drug treatments to see if they could be effective in helping COVID-19 patients. Bayer (OTC: BAYRY) is preparing to donate a large supply of an older malaria drug to the U.S. government, according to Axios.
While there's still plenty of testing that would need to be done, Bayer's anti-malarial treatment, chloroquine, is relatively inexpensive while possibly being just as effective as other antiviral COVID-19 treatments being developed right now. The most prominent of which is remdesivir, Gilead Sciences' (NASDAQ: GILD) former Ebola drug that's now in late-stage testing as a COVID-19 treatment.
Image source: Getty Images.
Source Fool.com
